339.00DKK-5.15%Mkt Cap: 5.54B DKKP/E: 3.30Last update: 2026-06-01
Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Pre…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap5.54B DKK
Enterprise Value4.86B DKK
Revenue (TTM)2.64B DKK
Gross Profit2.56B DKK
Net Income (TTM)1.69B DKK
Revenue/Share161.94 DKK
Last Price339.00 DKK
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees300
CountryDK
SectorHealthcare
IndustryBiotechnology
ISINDK0062266474
Valuation
P/E (Trailing)3.30
P/E (Forward)16.47
PEG—
EV/EBITDA2.25
EV/Revenue1.84
P/S2.21
P/B5.09
EPS (TTM)102.71
EPS (Forward)21.70
52W Range
293.0017% of range571.00
52W High571.00 DKK
52W Low293.00 DKK
Profitability
Gross Margin96.96%
Oper. Margin-51.94%
EBITDA Margin81.76%
Profit Margin64.11%
ROE147.53%
ROA128.09%
Growth
Revenue Growth-0.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF1.71B DKK
CapEx (TTM)19.16M DKK
FCF Margin50.51%
FCF Yield24.06%
Net Debt-975.52M DKK
Net Debt/EBITDA-0.45
Balance Sheet
Debt/Equity0.09
Current Ratio13.63
Quick Ratio13.58
Book Value/Sh70.16 DKK
Cash/Share66.31 DKK
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 DKK
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJun 30, 2025
Pay Date—
Analyst Consensus
Rating—
Target (Mean)451.50 DKK
Target Range403.00 DKK – 500.00 DKK
# Analysts2
Ownership
Shares Out.16.33M
Float6.28M
Insiders61.06%
Institutions26.02%
Technical
SMA 50343.10 (-1.2%)
SMA 200409.57 (-17.2%)
Beta0.25
S&P 52W Chg27.94%
Avg Vol (30d)30.66K
Avg Vol (10d)25.75K
Technical Indicators
RSI (14)59.2
MACD2.4430
MACD Signal-1.3354
MACD Hist.+3.7784
BB Upper358.38 DKK
BB Middle334.65 DKK
BB Lower310.92 DKK
BB Width14.18%
ATR (14)14.35 DKK
Vol Ratio (20d)3.01x